engage checkpoint medical linkedin twitter

Monitoring Anticoagulation: Yes or No?

Monitoring Anticoagulation: Yes or No?

A clinical discussion on anticoagulation monitoring

A clinical discussion on anticoagulation monitoring

Prof. Dimitrios Tsakiris, Prof. Michael Nagler

Listen to expert haematologists discuss anticoagulation monitoring in this educational podcast episode. You'll hear Prof. Tsakiris and Assoc. Prof. Nagler talk about:


  • Direct oral anticoagulants (DOAC) monitoring scenarios

When DOAC monitoring is necessary for acute situations like bleeding, surgery and thrombolysis, while recognising its limitations

  • Selective anticoagulation monitoring

Differentiating routine monitoring from critical drug level assessments and the impact on clinical decisions and patient care

  • Anti-Xa advantages

The benefits of Anti-Xa assays for anticoagulation monitoring, including potential standardisation and shifting from traditional assays for unfractionated heparin

This podcast is the first episode in a series on thrombosis in a different clinical situations.  The second episode, on cancer-associated thrombosis, is available here.  Episodes three and four will focus on venous thromboembolism and peri-operative thrombo-prophylaxis.  Check the COR2ED website for future episodes over the next few months.

Prof. Dimitrios Tsakiris


University of Basel


Prof. Michael Nagler


Inselspital University Hospital


preview next

Monitoring Anticoagulation: Yes or No?

time Podcast | open 20 min | Aug 2023

Subscribe to our podcast series on:

This programme was made for you:   your opinion matters

Share your feedback in just 4 clicks and help us to continue to create the content you need.

I agree that this educational programme:

Clinical Takeaways

  • DOAC monitoring is useful in special situations, but need not be done on a routine basis

  • DOAC choice and dosing should be guided by individual clinical characteristics rather than the monitoring results

  • Anti-Xa assays have key advantages in the determination of DOAC drug levels and in the monitoring of unfractionated heparin

  • Patients with vitamin K antagonists should be monitored in designated treatment programmes such as patient self-management

This educational programme is supported by an Independent Medical Education Grant from Viatris

HEMOSTASIS CONNECT is an initiative of COR2ED, supported by an Independent Educational Grant from Takeda and Viatris.

Other programmes of interest

preview next